Circassia, a biotech spin-out of Imperial College London developing cat and other allergy treatments, announces plans for $285m initial public offering.

Circassia, a biotechnology developing treatments for cat, grass, and other allergies, has revealed aims of raising a £175m ($285m) initial public offering (IPO), making it one of the largest UK floats in recent years.

The immunotherapy developer’s IPO could mark a bumper pay day for Imperial College London’s (ICL) tech transfer unit Imperial Innovations. The company has led a number of rounds alongside other investors such as Invesco Perpetual and Lansdowne Partners into Circassia, which total £105m. Innovations’ stake in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?